Cantargia Reports MDS and AML Response Rates in Phase 2a Expansion

At the June 30, 2026 data cutoff, 7 of 10 evaluable patients with higher-risk MDS responded to nadunolimab plus azacitidine, while 3 of 9 patients with adverse-risk relapsed or refractory AML responded to nadunolimab, azacitidine and venetoclax. The expansion is enrolling, with updated follow-up due at ASH in December.